39.54
price up icon1.72%   0.67
after-market Dopo l'orario di chiusura: 39.57 0.03 +0.08%
loading

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

pulisher
10:28 AM

Sarepta Receives FDA Platform Technology Designation for Viral Vector in SRP-9003 - marketscreener.com

10:28 AM
pulisher
10:25 AM

FDA Grants Platform Tech Designation To Viral Vector In Sarepta's SRP-9003 For LGMD Type 2E/R4 - marketscreener.com

10:25 AM
pulisher
10:24 AM

FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector - Nasdaq

10:24 AM
pulisher
09:55 AM

Sarepta (SRPT) Receives Key FDA Designation for Gene Therapy Vec - GuruFocus

09:55 AM
pulisher
09:55 AM

U.S. FDA Grants Platform Technology Designation to the Viral Vec - GuruFocus

09:55 AM
pulisher
09:40 AM

Sarepta gene therapy vector gets FDA platform designation - Investing.com

09:40 AM
pulisher
09:32 AM

Sarepta Therapeutics (SRPT) Granted FDA Platform Technology Designation to the Viral Vector Used in SRP-9003 - StreetInsider

09:32 AM
pulisher
09:30 AM

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 - Yahoo Finance

09:30 AM
pulisher
May 31, 2025

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

May 31, 2025
pulisher
May 29, 2025

SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent

May 29, 2025
pulisher
May 29, 2025

Intellia Plunges in Latest Example of Gene Therapy Troubles - Bloomberg.com

May 29, 2025
pulisher
May 29, 2025

July 11th Options Now Available For Sarepta Therapeutics (SRPT) - Nasdaq

May 29, 2025
pulisher
May 29, 2025

We Think The Compensation For Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) CEO Looks About Right - simplywall.st

May 29, 2025
pulisher
May 27, 2025

Oppenheimer to Host Important Meeting for SRPT Investors | SRPT Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Gene Therapy Death Worsens Picture for an Already Troubled Field - Barron's

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

FDA halts Rocket Pharma's gene therapy trial as patient dies - Reuters

May 27, 2025
pulisher
May 27, 2025

Was Jim Cramer Right About These 11 Stocks? - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

D. E. Shaw & Co. Inc. Sells 11,389,239 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

May 27, 2025
pulisher
May 27, 2025

Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces growth challenges - Investing.com

May 27, 2025
pulisher
May 26, 2025

Will Moderna's Rally Continue? - Forbes

May 26, 2025
pulisher
May 22, 2025

SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm | FinancialContent - FinancialContent

May 22, 2025
pulisher
May 22, 2025

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study - BioPharma Dive

May 22, 2025
pulisher
May 22, 2025

SRPT: HC Wainwright & Co. Reiterates Neutral Rating on Sarepta Therapeutics | SRPT Stock News - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Sto - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVID - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne - Yahoo Finance

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Rises as UK Greenlights Elevidys Study | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics (SRPT) Rallies After UK Lifts Clinical Hold on Elevidys Trials - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Stock Gains After U.K. Lets Elevidys Study Continue - MarketWatch

May 21, 2025
pulisher
May 21, 2025

Sarepta, Roche get U.K. feedback to continue dosing in Elevidys' Duchenne trial - Seeking Alpha

May 21, 2025
pulisher
May 21, 2025

Sarepta (SRPT) Gains UK Approval to Continue Gene Therapy Study - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy | SRPT Stock News - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Lowered by JP Morgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts - Benzinga

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | S - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Sarepta Therapeutics (SRPT) Price Target Reduced by JPMorgan | SRPT Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy - Yahoo Finance

May 19, 2025
pulisher
May 17, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne By Investing.com - Investing.com Nigeria

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Shares New Protein Expression and Safety Re - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Sarepta Therapeutics Presents Data at the American Society of Ge - GuruFocus

May 17, 2025
pulisher
May 16, 2025

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers - Endpoints News

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Reports Promising Results from ELEVIDYS Trial in Young Patients | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Sarepta (SRPT) Shows Promising Results for Duchenne Gene Therapy | SRPT Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Sarepta reports promising ELEVIDYS study results for Duchenne - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysi - GuruFocus

May 16, 2025
biotechnology ONC
$258.27
price up icon 2.60%
$111.14
price down icon 3.89%
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
Capitalizzazione:     |  Volume (24 ore):